Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry

Abstract

Background: Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors.

Methods: Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months. Changes in impairment parameters and correlations between impairment and patient/disease characteristics were assessed using generalized estimating equations.

Results: We included 194 patients in our analysis. After biological initiation, disease activity decreased significantly (PASI 11.2 at baseline versus 3.9 at 12 months, p < 0.001). Work-for-pay in this cohort was lower than in the Dutch general population (53% versus 67%, p = 0.01). In patients who had work-for-pay, presenteeism improved over time (5% at baseline versus 0% at 12 months, p = 0.04). Up to half of the patients reported impairments in ADL, which did not change over time. Associations between impairments and contextual factors varied, but all impairments were associated with worse mental/physical general functioning.

Conclusion: Patients with psoriasis using biologicals are less likely to have work-for-pay. Treatment improves the work productivity of employed patients, but we were unable to detect changes in ADL performance.

Keywords:

• Psoriasis
• work
• activities of daily living

Acknowledgements

The authors would like to thank Elke ter Haar and Sarah Thomas for their help with the comorbidity scores.

Ethics approval and informed consent

Under Dutch law, this non-interventional study is exempt from ethics review by the medical ethical committee. Informed consent was obtained from all patients before inclusion in the study.

Disclosure statement

TvH received personal fees from Eli Lily and Novartis, and non-financial support from UCB, outside the submitted work. JvdR carried out clinical trials for AbbVie, Celgene and Janssen and has received speaking fees/attended advisory boards from AbbVie, Janssen, BMS, Almirall, LEO Pharma and Eli Lilly and reimbursement for attending a symposium from Janssen, Pfizer, Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the department of dermatology of Radboud University Medical Center Nijmegen, the Netherlands. MO has acted as consultant for Eli Lilly. MT has carried out clinical trials for Abbvie, Amgen, Novartis, Eli Lilly, Leo Pharma, Cellgene. All trial funding is not personal but goes to the independent research fund of the department of dermatology of Bravis Hospital Bergen op Zoom, the Netherlands. He has received speaking fees/attended advisory boards from Novartis, UCB and Pfizer and reimbursement for attending a symposium from UCB. SD has attended advisory boards for Abbvie, Janssen and Leo Pharma, and has received a congress fee from Abbvie. MvD has received consulting fees or honorarium from Novartis, Abbvie, Pfizer, Leopharma, Sanofi, Lilly, Janssen and Celgene, has received a grant and payment for lectures including service on speakers bureaus from Novartis, Sanofi and Janssen outside the submitted work. JJM attended an advisory board for Novartis. RT has attended advisory boards from Leo Pharma and Eli Lilly Netherlands.

PvL has received funding from Wyeth for research; carried out clinical trials for Abbott, Janssen; has received speaking and consulting fees from Wyeth, Schering-Plough; has received reimbursement for attending a symposium from Schering-Plough, Pfizer; has attended advisory boards for Abbvie, Leo Pharma, Novartis and UCB. JV had received speaker fee from Galapagos Netherland b.v. outside the submitted work. EdJ has received research grants for the independent research fund of the department of dermatology of the Radboud university medical center Nijmegen, the Netherlands from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, and UCB for research on psoriasis and has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis or eczema including AbbVie, Amgen, Almirall, Celgene, Galapagos, Janssen Pharmaceutica, Lilly, Novartis, Leo Pharma, Sanofi and UCB. All funding is not personal but goes to the independent research fund of the department of dermatology of Radboud University medical center Nijmegen, the Netherlands. All other authors have no conflicts of interest to declare.

Data availability statement

The data underlying this article will be shared on reasonable request to the corresponding author.

Additional information

Funding

BioCAPTURE was funded by the University Medical Center St Radboud Foundation. This foundation received funding from AbbVie, Almirall, Eli Lilly, Janssen, Novartis, LEO Pharma, and UCB. All decisions concerning the design and execution of this study, data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review or manuscript approval were made independently from industrial contributions.